TO: those of us following the Eldepryl Story - Multiple recipients of
Listparksn
Item retrieved from GRATEFUL MED 28-02-96
Knoll J
The pharmaological basis of the beneficial effects of (-)deprenyl
(selegiline) in
Parkinson's and Alzheimer's diseases.
Department of Pharmacology, S emmelweis University of Medicine,
Budapest, Hungary.
Review Article: 67 References
J Neural Transm Suppl 1993;40:69-91
Unique identifier: 94125080
Abstract: (My"abstract of Abstract' - by quoting pertinent lines.)
1. "(-)Deprenyl (Selegiline, Jumex, Eldepryl, Movergan),
structurally closely related to phenylethylamine (PEA), is a
drug with
a unique pharmacological spectrum. It is a highly potent and
selective irreversible inhibitor of B-type monoamine oxidase
(MAO) and
interferes with the uptake of catecholamines and indirectly
acting
symphatomimetics..."
2. "...Maintenance on (-)deprenyl prevents the characteristic
age-related
morphological changes in the neuromelanin granules of the
neurocytes
in the substantia nigra. As a consequence of its complex
spectrum
of activity male rats maintained on (-) deprenyl live longer,
lose their
capacity to ejaculate later, show improved performance in
learning
tests and maintain this activity for a longer period,
significantly longer than
those on levodopa alone."
3 .",,,Freshly diagnosed patients treated with (-)deprenyl need
levodopa
later than their placebo-treated peers.. .."
4. "...Continuous administration of (-)deprenly improves the
performance of
patients with Alxheimer's disease..
Although we may not fully follow the mechanisms involved, and
realize this is a 1993 paper, the points delineated are
worthy of consideration and
discussion with our neurologists before taking precipitous action.
(Mary Manfredi) [log in to unmask]
